Site icon pharmaceutical daily

F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies

Data Presented at 2019 AACR Annual Meeting Supports Novel
Conditionally Active Biologics CAR-T Technology

ATLANTA–(BUSINESS WIRE)–F1 Oncology, Inc., a biotechnology company discovering and developing
adoptive cellular therapies (ACTs) for solid tumors, will present four
abstracts at the American Association of Cancer Research (AACR) 2019
Annual Meeting in Atlanta from March 29-April 3, 2019 that support novel
technologies to treat solid tumor malignancies.

F1 Oncology is developing these novel CAB-CAR-T therapies to target
solid tumors while minimizing the potential of on-target, off-tumor
activity. The four abstracts provide insight into the use of the
company’s proprietary CAB-CAR-T technology to increase the potential
safety of CAR-T therapeutics by turning the negative effects of the
tumor microenvironment (TME) into activating signals. They will
highlight proof of concept studies of same-day, point of care CAR-T and
use bioinformatics data driven methods to discover protein domain
combinations capable of selectively expanding CAR-T cells.

“The data to be presented highlight scientific progress that may greatly
simplify CAR-T therapy for solid tumor malignancies in the future,” said
Gregory Frost, Ph.D., Chairman and CEO of F1 Oncology. “The teams have
also made significant progress in our understanding of CAB-CAR-T’s role
in adoptive cellular therapy for solid tumors, and we look forward to
seeing the progress from ongoing clinical studies with these programs
through collaborators in Shanghai.”

The abstracts are available in the program section of the annual AACR
meeting website, and details for the poster presentations are as follows:

About F1 Oncology, Inc.

F1 Oncology, Inc. is a private Delaware corporation formed in November
2015 with operations in West Palm Beach, Florida, San Diego,
California and international affiliates in Cayman Islands, Hong Kong,
and Shanghai, China. F1 Oncology leverages its globally integrated
science, development and informatics teams located across multiple time
zones to accelerate the design, high-throughput screening, discovery and
development of adoptive cellular therapy (ACT) candidates. The company
is developing CAB-based ACT platforms to advance TME-restricted CAR-T
therapies for solid tumors, as well as highly scalable systems for
global deployment, beginning in Asia. Learn more at f1oncology.com.

Contacts

Hannah Bursack
+1 305-249-1211
hannah.bursack@rbbcommunications.com

Exit mobile version